DocLogic,
You are asking the right question about the two EDEN versions, and I want to be honest about something first. In my reply to BB, I said the Ori question dies. That was based on the biology: EDEN handles DC-T co-culture, the DePuyt Cluster E sorting solves potency at the source, and expansion is commodity. All of that is still true. But your point about the two EDEN versions and time advantage pushed me to think about the operational reality more carefully, and I think the answer is more nuanced than I initially stated.
Linda Powers addressed the EDEN versions at the December annual meeting. The original fully functional prototype was completed in 2023 and works. Engineers hired to build the GMP-compliant version instead did unwanted redesign work that extended the footprint by almost two feet, making it too large for the Grade C lab. The redesign was not wanted. Two new UK engineering teams are now working on the correct GMP version, with timing meshed to the Grade C suite construction through the first half of 2026. The 2023 prototype already handles DC-T cell co-culture. The EDEN patent describes serial and parallel chamber configurations, perfusion-controlled co-culture with chemokine gradient focusing, and T cell harvest within the same closed system. The 2024 deviation was a form factor problem, not a missing capability.
But here is where your instinct about Ori may point to something real, just not the thing most people are assuming.
Consider the timing gap. The science for the T cell product is ready. Kalinski presented clinical-grade data on April 29 showing alphaDC1-educated CTLs with two-hundred-fold enhanced dual-key recognition. The DePuyt paper published May 2 identified Cluster E sorting for manufacturing consistency. The Roswell Park patent portfolio NWBO licensed in June 2024 includes claims on CXCR4+ CD8+ T cells as drug products. Linda Powers confirmed at the annual meeting that the ovarian cancer combo trial is determined, lead institutions are on board, and a Pittsburgh manufacturing group is being built principally for Kalinski's DC products. The pipeline is ready to move.
But EDEN's GMP version is not ready yet. It is months away at minimum. And Linda Powers is resource-constrained, laser focused on MHRA approval and Sawston construction.
Here is a theory based on the logical evidence. The instruction event, the DC-T cell co-culture where Cluster E-sorted alphaDC1s educate polyclonal CTLs through the immunological synapse, is NWBO's moat. That is what the Kalinski licenses protect. That is what no other company can replicate. That must stay in-house in EDEN, even the 2023 prototype at clinical scale. The expansion step that follows, taking those correctly instructed T cells from millions to billions in suspension, is commodity. Any closed bioreactor can do it.
Ori is London-based. NWBO's Sawston facility is near Cambridge. Ori's IRO has FDA Advanced Manufacturing Technology designation. It operates in Grade C cleanrooms, the same grade NWBO is building. Ori's patented OriConnect system enables closed sterile fluid transfer between platforms, which could theoretically connect EDEN's co-culture output to IRO's expansion input without breaking sterility. Ori has 900+ characterization runs across 13+ partner sites and can yield up to 12 billion cells per run.
If NWBO wanted to move on the Kalinski ACT pipeline now rather than waiting for EDEN GMP, a bridge partnership where EDEN handles the instruction event and Ori handles the expansion step would let them get to clinical data faster. You protect the moat. You outsource the commodity step to an FDA-recognized platform in the same geography. And when EDEN GMP is ready, you bring the expansion back in-house and run the full workflow closed in one system.
That would explain Annalisa Jenkins' role more precisely than "regulatory and commercial execution for DCVax-L." Jenkins is a multi-product platform executive. Structuring a bridge manufacturing partnership that protects instruction event IP while accelerating time to clinic for a new product class is exactly the kind of deal her background equips her to negotiate. She is not there just for DCVax-L approval. She is there for what comes immediately after.
So to correct myself: the Ori question does not die. It evolves. Long-term, EDEN handles everything in one closed system and Ori has no role. Short-term, Ori could serve as a bridge that lets NWBO move on the ACT pipeline faster while EDEN GMP catches up. The moat is still the instruction event. The expansion step is still commodity. But commodity does not mean worthless when it buys you time.
Now on your point about DC heterogeneity and killer DCs. Credit where it is due. You flagged this years ago, and the concept was real. What the DePuyt paper adds is not the concept itself but three specific things no one had before: single-cell resolution of the alphaDC1 preparation at 149,535 cells, identification of three functionally antagonistic subpopulations within that specific product (Cluster E producing IL-12p70, Cluster D recruiting Tregs, Cluster F producing IL-23), and surface markers distinguishing them at baseline using existing GMP protocols. The heterogeneity you identified conceptually now has an actionable manufacturing solution. That solution, Cluster E sorting before co-culture, is what reduces the expansion requirement and makes any bridge partnership a temporary measure rather than a permanent dependency. Once every DC in the co-culture is an IRF8-high IL-12p70 producer, the T cell output is uniformly potent and the dose requirement drops because quality replaces quantity.
To stay on your question about end products: the desired end products are a DC for antigen capture and immune instruction, and a T cell for systemic effector deployment manufactured through DC-T co-culture. A macrophage arm for barrier clearance in desmoplastic solid tumors is a thesis supported by the evidence but not a confirmed NWBO program. EDEN handles the instruction for the first two. The expansion step for the T cell product is where Ori could serve as a bridge until EDEN GMP closes the loop. Long-term, everything runs in one closed system. Short-term, a bridge gets NWBO to ACT clinical data faster while the GMP engineering catches up.
That is a theory. But the pieces fit. And you pushed me to see it more clearly than I did in the BB reply.
Best wishes.
Market Data 
Markets 
AI
